Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cash from Operations: 2021-2025

Historic Cash from Operations for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $33.7 million.

  • Kiniksa Pharmaceuticals International's Cash from Operations rose 1606.13% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.9 million, marking a year-over-year increase of 814.81%. This contributed to the annual value of $25.7 million for FY2024, which is 93.14% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Cash from Operations of $33.7 million as of Q3 2025, which was up 19.89% from $28.1 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Cash from Operations high stood at $62.1 million for Q3 2022, and its period low was -$40.1 million during Q1 2021.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Cash from Operations averaged around $11.2 million, with its median value being $5.2 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 113.16% in 2024, then surged by 1,606.13% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Cash from Operations stood at -$18.9 million in 2021, then spiked by 38.70% to -$11.6 million in 2022, then surged by 137.36% to $4.3 million in 2023, then surged by 333.99% to $18.8 million in 2024, then spiked by 1,606.13% to $33.7 million in 2025.
  • Its Cash from Operations was $33.7 million in Q3 2025, compared to $28.1 million in Q2 2025 and $22.3 million in Q1 2025.